AIMS/HYPOTHESIS: Overproduction of phosphoprotein enriched in diabetes (PED, also known as phosphoprotein enriched in astrocytes-15 [PEA-15]) is a common feature of type 2 diabetes and impairs insulin action in cultured cells and in mice. Nevertheless, the potential role of PED in diabetic complications is still unknown. METHODS: We studied the effect of PED overproduction and depletion on kidney function in animal and cellular models. RESULTS: Transgenic mice overexpressing PED (PEDTg) featured age-dependent increases of plasma creatinine levels and urinary volume, accompanied by expansion of the mesangial area, compared with wild-type littermates. Serum and kidney levels of TGF-beta1 were also higher in 6- and 9-month-old PEDTg. Overexpression of PED in human kidney 2 cells significantly increased TGF-beta1 levels, SMAD family members (SMAD)2/3 phosphorylation and fibronectin production. Opposite results were obtained following genetic silencing of PED in human kidney 2 cells by antisense oligonucleotides. Inhibition of phospholipase D and protein kinase C-beta by 2-butanol and LY373196 respectively reduced TGF-beta1, SMAD2/3 phosphorylation and fibronectin production. Moreover, inhibition of TGF-beta1 receptor activity and SMAD2/3 production by SB431542 and antisense oligonucleotides respectively reduced fibronectin secretion by about 50%. TGF-beta1 circulating levels were significantly reduced in Ped knockout mice and positively correlated with PED content in peripheral blood leucocytes of type 2 diabetic patients. CONCLUSIONS/ INTERPRETATION: These data indicate that PED regulates fibronectin production via phospholipase D/protein kinase C-beta and TGF-beta1/SMAD pathways in kidney cells. Raised PED levels may therefore contribute to the abnormal accumulation of extracellular matrix and renal dysfunction in diabetes.
AIMS/HYPOTHESIS: Overproduction of phosphoprotein enriched in diabetes (PED, also known as phosphoprotein enriched in astrocytes-15 [PEA-15]) is a common feature of type 2 diabetes and impairs insulin action in cultured cells and in mice. Nevertheless, the potential role of PED in diabetic complications is still unknown. METHODS: We studied the effect of PED overproduction and depletion on kidney function in animal and cellular models. RESULTS:Transgenic mice overexpressing PED (PEDTg) featured age-dependent increases of plasma creatinine levels and urinary volume, accompanied by expansion of the mesangial area, compared with wild-type littermates. Serum and kidney levels of TGF-beta1 were also higher in 6- and 9-month-old PEDTg. Overexpression of PED in human kidney 2 cells significantly increased TGF-beta1 levels, SMAD family members (SMAD)2/3 phosphorylation and fibronectin production. Opposite results were obtained following genetic silencing of PED in human kidney 2 cells by antisense oligonucleotides. Inhibition of phospholipase D and protein kinase C-beta by 2-butanol and LY373196 respectively reduced TGF-beta1, SMAD2/3 phosphorylation and fibronectin production. Moreover, inhibition of TGF-beta1 receptor activity and SMAD2/3 production by SB431542 and antisense oligonucleotides respectively reduced fibronectin secretion by about 50%. TGF-beta1 circulating levels were significantly reduced in Ped knockout mice and positively correlated with PED content in peripheral blood leucocytes of type 2 diabeticpatients. CONCLUSIONS/ INTERPRETATION: These data indicate that PED regulates fibronectin production via phospholipase D/protein kinase C-beta and TGF-beta1/SMAD pathways in kidney cells. Raised PED levels may therefore contribute to the abnormal accumulation of extracellular matrix and renal dysfunction in diabetes.
Authors: D Kitsberg; E Formstecher; M Fauquet; M Kubes; J Cordier; B Canton; G Pan; M Rolli; J Glowinski; H Chneiweiss Journal: J Neurosci Date: 1999-10-01 Impact factor: 6.167
Authors: D Koya; M Haneda; H Nakagawa; K Isshiki; H Sato; S Maeda; T Sugimoto; H Yasuda; A Kashiwagi; D K Ways; G L King; R Kikkawa Journal: FASEB J Date: 2000-03 Impact factor: 5.191
Authors: G Condorelli; G Vigliotta; A Trencia; M A Maitan; M Caruso; C Miele; F Oriente; S Santopietro; P Formisano; F Beguinot Journal: Diabetes Date: 2001-06 Impact factor: 9.461
Authors: M Caruso; C Miele; F Oriente; A Maitan; G Bifulco; F Andreozzi; G Condorelli; P Formisano; F Beguinot Journal: J Biol Chem Date: 1999-10-01 Impact factor: 5.157
Authors: Qin Chen; Tsunaki Hongu; Takanobu Sato; Yi Zhang; Wahida Ali; Julie-Ann Cavallo; Adrianus van der Velden; Huasong Tian; Gilbert Di Paolo; Bernhard Nieswandt; Yasunori Kanaho; Michael A Frohman Journal: Sci Signal Date: 2012-11-06 Impact factor: 8.192
Authors: S Iovino; F Oriente; G Botta; S Cabaro; V Iovane; O Paciello; D Viggiano; G Perruolo; P Formisano; F Beguinot Journal: Cell Death Differ Date: 2012-01-27 Impact factor: 15.828
Authors: Laura A Maile; Katherine Gollahon; Christine Wai; Paul Dunbar; Walker Busby; David Clemmons Journal: J Diabetes Res Date: 2014-10-20 Impact factor: 4.011